These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 16388544)
1. CCR5 entry inhibitor problems: no clear answers yet. James JS AIDS Treat News; 2005; (416):4-5. PubMed ID: 16388544 [TBL] [Abstract][Full Text] [Related]
2. [CCR5 antagonists: a new class of antiretrovirals]. Peytavin G; Calvez V; Katlama C Therapie; 2009; 64(1):9-16. PubMed ID: 19463248 [TBL] [Abstract][Full Text] [Related]
3. The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. Maeda K; Nakata H; Ogata H; Koh Y; Miyakawa T; Mitsuya H Curr Opin Pharmacol; 2004 Oct; 4(5):447-52. PubMed ID: 15351348 [TBL] [Abstract][Full Text] [Related]
4. CCR5 antagonists for the treatment of HIV. Barber CG Curr Opin Investig Drugs; 2004 Aug; 5(8):851-61. PubMed ID: 15600241 [TBL] [Abstract][Full Text] [Related]
5. More problems with entry inhibitor. AIDS Patient Care STDS; 2006 May; 20(5):380. PubMed ID: 16758552 [No Abstract] [Full Text] [Related]
6. [CCR5 inhibitors. A new point of attack for HIV infection]. Heinzl S Med Monatsschr Pharm; 2007 Dec; 30(12):434-8; quiz 439-40. PubMed ID: 18196845 [No Abstract] [Full Text] [Related]
7. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Westby M; van der Ryst E Antivir Chem Chemother; 2010 Apr; 20(5):179-92. PubMed ID: 20413825 [TBL] [Abstract][Full Text] [Related]
9. CCR5 antagonists: a new tool in fighting HIV. Jülg B; Goebel FD J HIV Ther; 2005 Dec; 10(4):68-71. PubMed ID: 16519245 [TBL] [Abstract][Full Text] [Related]
10. First anti-CCR5 drug. Susman E AIDS; 2002 Aug; 16(12):N7. PubMed ID: 12214590 [No Abstract] [Full Text] [Related]
11. 1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1. Barber CG; Blakemore DC; Chiva JY; Eastwood RL; Middleton DS; Paradowski KA Bioorg Med Chem Lett; 2009 Feb; 19(4):1075-9. PubMed ID: 19171484 [TBL] [Abstract][Full Text] [Related]
12. HIV-1 entry inhibitors and virus emergence. D'Aquila RT; Hughes M; Johnson VA Nat Med; 1999 Oct; 5(10):1091. PubMed ID: 10502792 [No Abstract] [Full Text] [Related]
13. Rhinocerebral zygomycosis in an HIV-infected man during therapy with an investigational CCR5 inhibitor. Merchant S; Reichman R; Koval CE AIDS; 2007 Jul; 21(12):1666-9. PubMed ID: 17630574 [No Abstract] [Full Text] [Related]
14. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135 [TBL] [Abstract][Full Text] [Related]
16. Antiretrovirals in the pipeline: anticipated updates. Laurence J AIDS Read; 2005 Nov; 15(11):577-8. PubMed ID: 16329178 [No Abstract] [Full Text] [Related]
17. The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies. Armour D; de Groot MJ; Edwards M; Perros M; Price DA; Stammen BL; Wood A ChemMedChem; 2006 Jul; 1(7):706-9. PubMed ID: 16902922 [No Abstract] [Full Text] [Related]
18. Better results from vicriviroc with new Trofile test. Proj Inf Perspect; 2008 Dec; (47):12. PubMed ID: 19227563 [No Abstract] [Full Text] [Related]
19. Anti-HIV agents. Vicriviroc: is the risk of cancer increased? TreatmentUpdate; 2006; 18(4):5-6. PubMed ID: 17209230 [No Abstract] [Full Text] [Related]
20. CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection. Lim JK; Glass WG; McDermott DH; Murphy PM Trends Immunol; 2006 Jul; 27(7):308-12. PubMed ID: 16753343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]